share_log

XPHOZAH Granted Orphan Drug Designation By U.S. FDA For The Treatment Of Pediatric Hyperphosphatemia

Benzinga ·  11/16/2023 05:02

XPHOZAH Granted Orphan Drug Designation By U.S. FDA For The Treatment Of Pediatric Hyperphosphatemia

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment